Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities

Protein and Cell

Volumn 6, Issue 2, 2015, Pages 88-100

  Zhang, Caiguo ^a   Zhang, Fan ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

cell cycle; DNA repair; Iron tumorigenesis; p53; Wnt

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CD71 ANTIGEN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEPCIDIN; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR; IRON; IRON CHELATING AGENT; IRON REGULATORY PROTEIN 1; PROTEIN KINASE B; PROTEIN P53; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TACHPYRIDINE; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE COURSE; DNA REPAIR; DNA REPLICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; IRON METABOLISM; LIVER CELL CARCINOMA; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

CARCINOGENESIS; HOMEOSTASIS; HUMANS; IRON; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84925517973     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-014-0119-z     Document Type: Article

References (125)

1. Al Robaian M, Chiam KY, Blatchford DR, Dufes C (2014) Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas. Nanomedicine (Lond) 9:421–434
2. Aleman MR, Santolaria F, Batista N, de La Vega M, Gonzalez-Reimers E, Milena A, Llanos M, Gomez-Sirvent JL (2002) Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 19:21–26
3. Anderson GJ, Vulpe CD (2009) Mammalian iron transport. Cell Mol Life Sci 66:3241–3261
4. Andrews NC, Schmidt PJ (2007) Iron homeostasis. Annu Rev Physiol 69:69–85
5. Armaghany T, Wilson JD, Chu Q, Mills G (2012) Genetic alterations in colorectal cancer. Gastrointest Cancer Res 5:19–27
6. Aye Y, Li M, Long MJ, Weiss RS (2014) Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. doi:10.1038/onc.2014.155
7. Beckman LE, Hagerstrand I, Stenling R, Van Landeghem GF, Beckman L (2000) Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 59:317–322
8. Berger T, Cheung CC, Elia AJ, Mak TW (2010) Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci USA 107:2995–3000
9. Bracci PM (2012) Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol Carcinog 51:53–63
10. Burandt E, Grunert M, Lebeau A, Choschzick M, Quaas A, Janicke F, Muller V, Scholz U, Bokemeyer C, Petersen C, et al. (2014) Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer. doi:10.1007/s12282-014-0538-y
11. Buss JL, Torti FM, Torti SV (2003) The role of iron chelation in cancer therapy. Curr Med Chem 10:1021–1034
12. Carpagnano GE, Lacedonia D, Palladino GP, Koutelou A, Martinelli D, Orlando S, Foschino-Barbaro MP (2012) Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes? Eur J Clin Investig 42:478–486
13. Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol 73:200–210
14. Chen G, Fillebeen C, Wang J, Pantopoulos K (2007) Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis 28:785–791
15. Chen Y, Zhang Z, Yang K, Du J, Xu Y, Liu S (2014) Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene. doi:10.1038/onc.2014.310
16. Cheng Z, Dai LL, Song YN, Kang Y, Si JM, Xia J, Liu YF (2014) Regulatory effect of iron regulatory protein-2 on iron metabolism in lung cancer. Genet Mol Res 13:5514–5522
17. Cho H, Kim JH (2009) Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem 57:513–521
18. Choi AM, Alam J (1996) Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 15:9–19
19. Crepin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA (2010) Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res 70:5497–5506
20. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820:291–317
21. Dayani PN, Bishop MC, Black K, Zeltzer PM (2004) Desferoxamine (DFO)–mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 67:367–377
22. Denic S, Agarwal MM (2007) Nutritional iron deficiency: an evolutionary perspective. Nutrition 23:603–614
23. Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Fargion S, Valenti L (2010) Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 176:1006–1017
24. Duarte DC, Nicolau A, Teixeira JA, Rodrigues LR (2011) The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 94:66–76
25. Dunn LL, Suryo Rahmanto Y, Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol 17:93–100
26. Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J et al (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 114:3064–3073
27. Emanuele D, Tuason I, Edwards QT (2014) HFE-associated hereditary hemochromatosis: overview of genetics and clinical implications for nurse practitioners in primary care settings. J Am Assoc Nurse Pract 26:113–122
28. Enyedy EA, Primik MF, Kowol CR, Arion VB, Kiss T, Keppler BK (2011) Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans 40:5895–5905
29. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390–5395
30. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613
31. Fu D, Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 110:752–761
32. Gkouvatsos K, Papanikolaou G, Pantopoulos K (2012) Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 1820:188–202
33. Hamalainen P, Saltevo J, Kautiainen H, Mantyselka P, Vanhala M (2012) Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc Diabetol 11:116
34. Hewitson KS, McNeill LA, Elkins JM, Schofield CJ (2003) The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 31:510–515
35. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D’Alo F, Larocca LM, Raymakers RA, Swinkels DW et al (2010) Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 28:2538–2543
36. Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE (2007) Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev 16:1784–1794
37. Hou Y, Zhang S, Wang L, Li J, Qu G, He J, Rong H, Ji H, Liu S (2012) Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene 511:398–403
38. Iwasaki K, Ray PD, Huang BW, Sakamoto K, Kobayashi T, Tsuji Y (2013) Role of AMP-activated protein kinase in ferritin H gene expression by resveratrol in human T cells. Biochemistry 52:5075–5083
39. Jakszyn PG, Allen NE, Lujan-Barroso L, Gonzalez CA, Key TJ, Fonseca-Nunes A, Tjonneland A, Fons-Johnsen N, Overvad K, Teucher B et al (2012) Nitrosamines and heme iron and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 21:547–551
40. Jiang XP, Elliott RL, Head JF (2010) Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res 30:759–765
41. Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA et al (2013) Inhibition of beta2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One 8:e68366
42. Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol 33:1695–1700
43. Kaplan CD, Kaplan J (2009) Iron acquisition and transcriptional regulation. Chem Rev 109:4536–4552
44. Keith B, Johnson RS, Simon MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12:9–22
45. Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26:1494–1497
46. Koreth J, Antin JH (2010) Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica 95:364–366
47. Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 127:S79–86
48. Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M (2010) Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol 27:268–277
49. Kumar D, Viberg J, Nilsson AK, Chabes A (2010) Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids Res 38:3975–3983
50. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM (1997) Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272:5375–5381
51. Lee SH, Pyo CW, Hahm DH, Kim J, Choi SY (2009) Iron-saturated lactoferrin stimulates cell cycle progression through PI3K/Akt pathway. Mol Cells 28:37–42
52. Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF et al (2009) Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res 69:8579–8584
53. Leng X, Wu Y, Arlinghaus RB (2011) Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol 226:309–314
54. Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, To C, Panchal D, Tsao MS (2012) Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One 7:e46677
55. Lill R, Hoffmann B, Molik S, Pierik AJ, Rietzschel N, Stehling O, Uzarska MA, Webert H, Wilbrecht C, Muhlenhoff U (2012) The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 1823:1491–1508
56. Lin X, Yang H, Zhou L, Guo Z (2011) Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 51:97–106
57. Lok CN, Ponka P (1999) Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274:24147–24152
58. Lovejoy DB, Richardson DR (2003) Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem 10:1035–1049
59. MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9–26
60. MacKenzie EL, Iwasaki K, Tsuji Y (2008) Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 10:997–1030
61. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S et al (2010) In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116:3635–3644
62. Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA (2012) Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer 12:169
63. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444
64. Martin JH, Alalami O, Yaqoob F (2000) Differential effects of retinoids on nitric oxide production by promonocytic U937 cells and ZR-75-1 human breast cancer cells. Oncol Rep 7:219–223
65. Miller JL (2013) Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med 3:a011866. doi:10.1101/cshperspect.a011866
66. Miyabe I, Kunkel TA, Carr AM (2011) The major roles of DNA polymerases epsilon and delta at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet 7:e1002407
67. Molina-Montes E, Wark PA, Sanchez MJ, Norat T, Jakszyn P, Lujan-Barroso L, Michaud DS, Crowe F, Allen N, Khaw KT et al (2012) Dietary intake of iron, heme-iron and magnesium and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. Int J Cancer 131:E1134–1147
68. Moser JC, Rawal M, Wagner BA, Du J, Cullen JJ, Buettner GR (2013) Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Redox Biol 2:22–27
69. Muckenthaler MU, Galy B, Hentze MW (2008) Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28:197–213
70. Mukhopadhyay CK, Mazumder B, Fox PL (2000) Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem 275:21048–21054
71. Munoz M, Gomez-Ramirez S, Martin-Montanez E, Auerbach M (2014) Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol 20:1972–1985
72. Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1:81–89
73. Ornstein DL, Zacharski LR (2007) Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer 58:115–126
74. Orrenius S, Nicotera P, Zhivotovsky B (2011) Cell death mechanisms and their implications in toxicology. Toxicol Sci 119:3–19
75. Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK et al (2010) HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 51:1311–1318
76. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L (2012) Mechanisms of mammalian iron homeostasis. Biochemistry 51:5705–5724
77. Park KS, Kim H, Kim NG, Cho SY, Choi KH, Seong JK, Paik YK (2002) Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology 35:1459–1466
78. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117:1926–1932
79. Preston BD, Albertson TM, Herr AJ (2010) DNA replication fidelity and cancer. Semin Cancer Biol 20:281–293
80. Pusatcioglu CK, Nemeth E, Fantuzzi G, Llor X, Freels S, Tussing-Humphreys L, Cabay RJ, Linzmeier R, Ng D, Clark J et al (2014) Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond) 11:21
81. Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, Ford SJ, Stones DH, Iqbal TH, Tselepis C et al (2012) Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep 2:270–282
82. Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, Bernhardt PV (2009) 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem 52:1459–1470
83. Romero A, Ramos E, de Los Rios C, Egea J, Del Pino J, Reiter RJ (2014) A review of metal-catalyzed molecular damage: protection by melatonin. J Pineal Res 56:343–370
84. Rossi E (2005) Hepcidin–the iron regulatory hormone. Clin Biochem Rev 26:47–49
85. Rouault TA (2003) How mammals acquire and distribute iron needed for oxygen-based metabolism. PLoS Biol 1:E79
86. Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2:406–414
87. Sakurai K, Sohda T, Ueda S, Tanaka T, Hirano G, Yokoyama K, Morihara D, Aanan A, Takeyama Y, Irie M et al (2014) Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue. Hepatogastroenterology 61:426–430
88. Sarkar A, Sil PC (2014) Iron oxide nanoparticles mediated cytotoxicity via PI3K/AKT pathway: role of quercetin. Food Chem Toxicol 71:106–115
89. Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X et al (2014) Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep 7:180–193
90. Shiiba M, Saito K, Fushimi K, Ishigami T, Shinozuka K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A, Sakamoto Y et al (2013) Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. Int J Oncol 42:1197–1204
91. Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP (2011) Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 126:63–71
92. Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett 267:204–215
93. Siriwardana G, Seligman PA (2013) Two cell cycle blocks caused by iron chelation of neuroblastoma cells: separating cell cycle events associated with each block. Physiol Rep 1:e00176
94. Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M et al (2011) Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res 71:7628–7639
95. Stocker R (1990) Induction of haem oxygenase as a defence against oxidative stress. Free Radic Res Commun 9:101–112
96. Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274:24142–24146
97. Tammariello AE, Milner JA (2010) Mouse models for unraveling the importance of diet in colon cancer prevention. J Nutr Biochem 21:77–88
98. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM (2009) Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood) 234:693–702
99. Tenga MJ, Lazar IM (2014) Proteomic study reveals a functional network of cancer markers in the G1-Stage of the breast cancer cell cycle. BMC Cancer 14:710
100. Thomas C, Mackey MM, Diaz AA, Cox DP (2009) Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep 14:102–108
101. Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer 13:342–355
102. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10:1343–1374
103. Tsui KH, Chung LC, Wang SW, Feng TH, Chang PL, Juang HH (2013) Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol 51:131–141
104. Vakkala M, Paakko P, Soini Y (2000) eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 17:667–671
105. Valerio LG (2007) Mammalian iron metabolism. Toxicol Mech. Methods 17:497–517
106. Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffman RM (1990) The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture. Cancer Res 50:6095–6099
107. von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA (2012) Wnt signaling in myogenesis. Trends Cell Biol 22:602–609
108. Wang J, Pantopoulos K (2002) Conditional derepression of ferritin synthesis in cells expressing a constitutive IRP1 mutant. Mol Cell Biol 22:4638–4651
109. Wang J, Li Q, Ou Y, Han Z, Li K, Wang P, Zhou S (2011) Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 34:987–995
110. Wang N, Wei H, Yin D, Lu Y, Zhang Y, Jiang D, Jiang Y, Zhang S (2014) Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo. Int J Clin Exp Pathol 7:4016–4023
111. Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM (2003) Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol 23:178–185
112. Wu Y, Brosh RM Jr (2012) DNA helicase and helicase-nuclease enzymes with a conserved iron-sulfur cluster. Nucleic Acids Res 40:4247–4260
113. Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cycling of stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys 346:180–186
114. Xiong W, Wang L, Yu F (2014) Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol 31:28
115. Xue X, Shah YM (2013) Intestinal iron homeostasis and colon tumorigenesis. Nutrients 5:2333–2351
116. Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ, Shah YM (2012) Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res 72:2285–2293
117. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A 106:3913–3918
118. Yang J, McNeish B, Butterfield C, Moses MA (2013) Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 27:45–50
119. Yildirim A, Meral M, Kaynar H, Polat H, Ucar EY (2007) Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit 13: CR195–200
120. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883
121. Zhang C (2014) Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 5:750–760
122. Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM (2008) Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem 283:33911–33918
123. Zhang F, Tao Y, Zhang Z, Guo X, An P, Shen, Y, Wu Q, Yu Y, Wang F (2012) Metalloreductase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses. Haematologica 97:1826–1835
124. Zhang C, Liu G, Huang M (2014) Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition. Front Biol (Beijing) 9:104–113
125. Zhao N, Gao J, Enns CA, Knutson MD (2010) ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem 285:32141–32150